Excessive Daytime Somnolence: Clinical Trials

2 trials for Excessive Daytime Somnolence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Withdrawn 1
Phase 31Completed 1

Follow Excessive Daytime Somnolence: new trials by email Literature Review of Excessive Daytime Somnolence trials Research Report on Excessive Daytime Somnolence

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study
Valiloxybate, Placebo - Parkinson Disease, Excessive Daytime Somnolence
Phase 2WithdrawnXWPharma2021-11-012025-03-19
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
Caffeine 100-200 mg BID, placebo - Parkinson's Disease, Excessive Daytime Somnolence
Phase 2 / Phase 3CompletedRon Postuma582007-04-012015-04-16

Narrower conditions

Disorders of Excessive Somnolence (2)  ·  Parkinson Disease (2)

Broader conditions

Basal Ganglia Diseases (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Dyssomnias (2)  ·  Mental Disorders (2)  ·  Movement Disorders (2)  ·  Nervous System Diseases (2)  ·  Neurodegenerative Diseases (2)  ·  Parkinsonian Disorders (2)  ·  Sleep Disorders, Intrinsic (2)  ·  Sleep Wake Disorders (2)  ·  Synucleinopathies (2)

Interventions

BID protein, human (1)  ·  Caffeine (1)

Sponsors

Ron Postuma (1)  ·  XWPharma (1)

Countries

Canada (1)

Top investigators

Daniel M. Canafax, PharmD (1)  ·  Ron Postuma, MD, MSc (1)